Current studies indicate that the majority of cancer patients undergoing conventional therapies believe that the treatment is “curative.” Meaning these patients believe that they might be cured. Mesothelioma is currently an incurable cancer. “Current treatments, including surgery and chemotherapy, have limited efficacy and unpleasant side effects..”
The point of the article linked below is for the mesothelioma patient to think outside the box. Find an oncologist that specializes in mesothelioma and ask him/her about therapies beyond the “standard-of-care.”
The fact is that there are a host of evidence-based non-conventional therapies that have been shown to either enhance the efficacy of meso chemotherapy or kill meso by itself.
I am a long-term cancer survivor and cancer coach. I work with cancer patients and survivors to research and identify both conventional and evidence-based non-conventional therapies to enhance both length of life and quality of life.
To learn more about mesothelioma therapies, both conventional and non-conventional, scroll down the page, post a question or comment and I will reply ASAP.
“A new targeted therapy for asbestos-related tumours has shown promise in an animal model. The results, raise hopes of a new therapy for this currently incurable cancer…Malignant mesothelioma (MMs) is a rare form of cancer, most commonly caused by exposure to asbestos. It tends to be diagnosed decades after exposure occurs, so is rarely caught early. Current treatments, including surgery and chemotherapy, have limited efficacy and unpleasant side effects...
The new therapy is more effective and less toxic than doxorubicin alone…Tumours shrank, the cancer cells proliferated less, and the animals were able more or less to maintain their weight and health throughout the treatment. Overall, the data suggest that targeted therapy may prove better than chemotherapy alone…
Using this targeting approach, the authors were able to reduce the dose of doxorubicin used four-fold thus almost eliminating side effects and toxicity. And because the treatment appears to reduce the number of proliferating tumour cells, it may prove useful early on, when pre-malignant or malignant MM cells are first observed, but before disease has been confirmed by histology.”
“Results– Targeted therapy (APMS-MB-DOX at 0.05 mg/kg) was more effective than DOX low (0.05 mg/kg) and less toxic than treatment with DOX high (0.2 mg/kg). It also resulted in the reduction of tumor volume without loss of animal health and weight, and significantly decreased tumor cell proliferation. High pressure liquid chromatography (HPLC) of tumor tissue confirmed that APMS-MB-DOX particles delivered DOX to target tissue.
Conclusions- Data suggest that targeted therapy results in greater chemotherapeutic efficacy with fewer adverse side effects than administration of DOX alone. Targeted microparticles are an attractive option for localized drug delivery.”